Education
About Us
Working with TipRanks
Follow Us
Chromocell Therapeutics Corp (CHRO)
:CHRO
Total Valuation
Chromocell Therapeutics Corp has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Chromocell Therapeutics Corp has 6,103,813 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,103,813
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chromocell Therapeutics Corp’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-1.85M
Employee Count4
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Chromocell Therapeutics Corp is ―. Chromocell Therapeutics Corp’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Chromocell Therapeutics Corp had revenue of 0.00 and earned -7.38M in profits. Earnings per share was -1.28.
Revenue0.00
Gross Profit-2.58M
Operating Income-6.86M
Pretax Income-7.38M
Net Income-7.38M
EBITDA-6.86M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -5.48M and capital expenditures 0.00, giving a free cash flow of -5.48M billion.
Operating Cash Flow-5.48M
Free Cash Flow-5.48M
Free Cash Flow per Share-0.90
Dividends & Yields
Chromocell Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.27
52-Week Price Change-8.33%
50-Day Moving Average1.64
200-Day Moving Average1.12
Relative Strength Index (RSI)48.23
Average Volume (3m)1.33M
Important Dates
Chromocell Therapeutics Corp upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Chromocell Therapeutics Corp as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Chromocell Therapeutics Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Chromocell Therapeutics Corp EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Chromocell Therapeutics Corp has $1.25M in cash and marketable securities with $540.43K in debt, giving a net cash position of $1.03M billion.
Cash & Marketable Securities$1.25M
Total Debt$540.43K
Net Cash$1.03M
Net Cash Per Share$0.17
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Chromocell Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―